Early stage life sciences company iBIONICS has had “a phenomenal year of growth and learning,” says CEO and co-founder Suzanne Grant.
The company, which is developing a bionic-eye system to restore vision in people with retinal degenerative diseases, has reached combined private and public funding goals of US$2.5 million and added another $1.5 million in grants; it also expects to finalize additional pre-seed financing in the next two quarters.
The firm has secured an exclusive worldwide licence for its prototype and has recently celebrated several other business and technical milestones.
OBJ360 (Sponsored)
How CN Cycle for CHEO powers world-class cancer research
“Kids shouldn’t have to die of cancer,” says Tamy Bell when asked why Dr. Shawn Beug’s research at CHEO is so important. Bell, after all, should know: Not only is
Sharing “PapaJo’s” story to shine the spotlight on the Campaign to Create Tomorrow
Visitors to the seventh floor of The Ottawa Hospital’s General campus may do a double take outside Room 7123. A plaque beside the door references “PapaJo” Johns. Who, you may
Ms. Grant and iBIONICS were also chosen to exhibit at the Accessibility Innovation Showcase at the Invictus Games in Toronto in September.
